Cancer Treatment Results  Survival Rates Cancer Treatments / Therapy Results

Click here to go back to your search results.

Non-Hodgkin's Lymphoma treatment details. Biologic therapy. University of Rochester, Rochester, NY, United States

Survival: 8.0 months
Toxicity Grade: 5
Treatments: Biologic therapy
Country: United States
City/State/Province: Rochester, NY
Hospital: University of Rochester
Journal: Link
Date: 7/2015

This phase 2 study involved 37 peripheral T Cell lymphoma patients who had been previously treated. The median patient age was 62 years and 65% were male.

Patients received biologic therapy with alisertib, an oral aurora A kinase (AAK) inhibitor.

There was one treatment-related death due to grade 5 sepsis (infection). Grade 3 or higher neutropenia, mucositis (inflammation of the lining of the digestive tract), and anemia were also reported.

The median overall survival was 8 months.

Correspondence: Dr. Paul M. Barr; email:

E-mail to a Friend Email Physician More Information